Posted by Michael Wonder on 09 Sep 2022
Spectrum Pharmaceuticals receives FDA approval for Rolvedon (eflapegrastim-xnst) injection
9 September 2022 - First novel long-acting G-CSF product approved in over 20 years.
Spectrum Pharmaceuticals today announced that the US FDA has approved Rolvedon (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
